Moderate-to-severe chronic plaque psoriasis
Clinical trials for Moderate-to-severe chronic plaque psoriasis explained in plain language.
Never miss a new study
Get alerted when new Moderate-to-severe chronic plaque psoriasis trials appear
Sign up with your email to follow new studies for Moderate-to-severe chronic plaque psoriasis, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New psoriasis drug shows promise in chinese trial
Disease control CompletedThis phase 3 study tested the drug bimekizumab in 133 Chinese adults with moderate to severe plaque psoriasis. Participants received either bimekizumab or a placebo for 16 weeks. The main goals were to see if bimekizumab could clear at least 90% of psoriasis (PASI90) and achieve …
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New psoriasis drug shows promise in major trial
Disease control CompletedThis study tested a new drug called bimekizumab in 567 adults with moderate to severe plaque psoriasis. Participants received either bimekizumab, a placebo, or another active drug. The main goal was to see how well bimekizumab cleared skin lesions after 16 weeks. Results showed s…
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug bimekizumab shows promise in clearing psoriasis in phase 3 trial
Disease control CompletedThis phase 3 study tested bimekizumab, a drug given by injection, against a placebo in 435 adults with moderate to severe plaque psoriasis. The main goal was to see how many people achieved at least 90% skin clearing after 16 weeks. The trial also looked at complete clearing and …
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New psoriasis drug bimekizumab outperforms secukinumab in major trial
Disease control CompletedThis Phase 3 trial tested bimekizumab against secukinumab and placebo in 743 adults with moderate to severe plaque psoriasis. The main goal was to see how many patients achieved complete skin clearance (PASI100) at 16 weeks. Bimekizumab showed superior results compared to secukin…
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Psoriasis drug bimekizumab shows promise in Long-Term safety trial
Disease control CompletedThis study looked at the long-term safety and tolerability of bimekizumab in over 1,300 adults with moderate to severe plaque psoriasis. Participants who completed earlier studies received bimekizumab injections over several years. The main goal was to track side effects and see …
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for kids with psoriasis: cosentyx® shows promise in chinese study
Disease control CompletedThis study followed 42 children aged 6 to 17 with moderate to severe plaque psoriasis in China who were treated with Cosentyx® (secukinumab) for up to 52 weeks. The goal was to see how safe and effective the drug is in real-world settings. Researchers tracked side effects and mea…
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New psoriasis drug shows promise in large trial
Disease control CompletedThis Phase 3 trial tested a new drug called JS005 in 747 adults with moderate-to-severe plaque psoriasis. JS005 is an antibody that blocks IL-17A, a protein that drives inflammation in psoriasis. The study compared JS005 to a placebo to see if it could improve skin clearance, mea…
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New psoriasis drug could rival stelara in major trial
Disease control CompletedThis phase 3 trial tested whether Bmab 1200, a biosimilar of the drug Stelara, works as well as Stelara for people with moderate to severe plaque psoriasis. 384 adults received either Bmab 1200 or Stelara over 40 weeks. The main goal was to see how much psoriasis symptoms improve…
Matched conditions: MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
Phase 3 • Sponsor: Biocon Biologics UK Ltd • Aim: Disease control
Last updated Jun 26, 2026 16:50 UTC